Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 29 | Orphanet Journal of Rare Diseases

Figure 29

From: Fabry disease

Figure 29

Median estimated glomerular filtration rate (eGFR; ml/min per 1.73 m2) over time in 44 patients treated with agalsidase beta for 54 months: Patients in the “as treated” population maintained a stable median eGFR during the 54-month treatment. Subgroup analyses of patients who were stratified by baseline proteinuria (>1 g/24 h versus <1 g/24 h) showed differences in the rate of eGFR decline during the 54-mo treatment period [309]. High (>1 g/24 h) baseline proteinuria was associated with higher rate of eGFR decline and increased probability of renal events.

Back to article page